Covaxin Set To Be Evaluated In US, Says Maker Bharat Biotech

Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US.

Bharat Biotech on Saturday said its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US.

In a statement, Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, noted that the American health regulator -- the US Food and Drug Administration (FDA) -- has lifted its clinical hold to evaluate the COVID-19 vaccine candidate BBV152, known as Covaxin outside the US.

Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US.

Ocugen Inc is co-developing the Covaxin vaccine candidate for COVID-19 in the US and Canada.